ORGAN DOSES AND EFFECTIVE DOSE FOR FIVE PET RADIOPHARMACEUTICALS
(2016) In Radiation Protection Dosimetry 169(1-4). p.8-253- Abstract
Diagnostic investigations with positron-emitting radiopharmaceuticals are dominated by (18)F-fluorodeoxyglucose ((18)F-FDG), but other radiopharmaceuticals are also commercially available or under development. Five of them, which are all clinically important, are (18)F-fluoride, (18)F-fluoroethyltyrosine ((18)F-FET), (18)F-deoxyfluorothymidine ((18)F-FLT), (18)F-fluorocholine ((18)F-choline) and (11)C-raclopride. To estimate the potential risk of stochastic effects (mainly lethal cancer) to a population, organ doses and effective dose values were updated for all five radiopharmaceuticals. Dose calculations were performed using the computer program IDAC2.0, which bases its calculations on the ICRP/ICRU adult reference voxel phantoms and... (More)
Diagnostic investigations with positron-emitting radiopharmaceuticals are dominated by (18)F-fluorodeoxyglucose ((18)F-FDG), but other radiopharmaceuticals are also commercially available or under development. Five of them, which are all clinically important, are (18)F-fluoride, (18)F-fluoroethyltyrosine ((18)F-FET), (18)F-deoxyfluorothymidine ((18)F-FLT), (18)F-fluorocholine ((18)F-choline) and (11)C-raclopride. To estimate the potential risk of stochastic effects (mainly lethal cancer) to a population, organ doses and effective dose values were updated for all five radiopharmaceuticals. Dose calculations were performed using the computer program IDAC2.0, which bases its calculations on the ICRP/ICRU adult reference voxel phantoms and the tissue weighting factors from ICRP publication 103. The biokinetic models were taken from ICRP publication 128. For organ doses, there are substantial changes. The only significant change in effective dose compared with previous estimations was a 46 % reduction for (18)F-fluoride. The estimated effective dose in mSv MBq(-1) was 1.5E-02 for (18)F-FET, 1.5E-02 for (18)F-FLT, 2.0E-02 for (18)F-choline, 9.0E-03 for (18)F-fluoride and 4.4E-03 for (11)C-raclopride.
(Less)
- author
- Andersson, Martin LU ; Johansson, L ; Mattsson, Sören LU ; Minarik, David LU and Leide-Svegborn, Sigrid LU
- organization
- publishing date
- 2016-06
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Radiation Protection Dosimetry
- volume
- 169
- issue
- 1-4
- pages
- 8 - 253
- publisher
- Oxford University Press
- external identifiers
-
- pmid:26977075
- scopus:84979055642
- wos:000383492100039
- ISSN
- 1742-3406
- DOI
- 10.1093/rpd/ncw033
- language
- English
- LU publication?
- yes
- id
- 38a1c133-2c3c-4e9b-a910-aab0d00a3412
- date added to LUP
- 2016-04-12 11:55:18
- date last changed
- 2024-04-18 21:49:11
@article{38a1c133-2c3c-4e9b-a910-aab0d00a3412, abstract = {{<p>Diagnostic investigations with positron-emitting radiopharmaceuticals are dominated by (18)F-fluorodeoxyglucose ((18)F-FDG), but other radiopharmaceuticals are also commercially available or under development. Five of them, which are all clinically important, are (18)F-fluoride, (18)F-fluoroethyltyrosine ((18)F-FET), (18)F-deoxyfluorothymidine ((18)F-FLT), (18)F-fluorocholine ((18)F-choline) and (11)C-raclopride. To estimate the potential risk of stochastic effects (mainly lethal cancer) to a population, organ doses and effective dose values were updated for all five radiopharmaceuticals. Dose calculations were performed using the computer program IDAC2.0, which bases its calculations on the ICRP/ICRU adult reference voxel phantoms and the tissue weighting factors from ICRP publication 103. The biokinetic models were taken from ICRP publication 128. For organ doses, there are substantial changes. The only significant change in effective dose compared with previous estimations was a 46 % reduction for (18)F-fluoride. The estimated effective dose in mSv MBq(-1) was 1.5E-02 for (18)F-FET, 1.5E-02 for (18)F-FLT, 2.0E-02 for (18)F-choline, 9.0E-03 for (18)F-fluoride and 4.4E-03 for (11)C-raclopride.</p>}}, author = {{Andersson, Martin and Johansson, L and Mattsson, Sören and Minarik, David and Leide-Svegborn, Sigrid}}, issn = {{1742-3406}}, language = {{eng}}, number = {{1-4}}, pages = {{8--253}}, publisher = {{Oxford University Press}}, series = {{Radiation Protection Dosimetry}}, title = {{ORGAN DOSES AND EFFECTIVE DOSE FOR FIVE PET RADIOPHARMACEUTICALS}}, url = {{http://dx.doi.org/10.1093/rpd/ncw033}}, doi = {{10.1093/rpd/ncw033}}, volume = {{169}}, year = {{2016}}, }